Advances in renal bone disease: Osteoporosis and chronic kidney disease

Current Rheumatology Reports

Volumn 11, Issue 3, 2009, Pages 185-190

  Sprague, Stuart M ^a   Barnato, Sara ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALUMINUM; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; LANTHANUM CARBONATE; PARATHYROID HORMONE[1-34]; PARICALCITOL; PHOSPHATE BINDING AGENT; RISEDRONIC ACID; SEVELAMER;

BONE BIOPSY; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY DISEASE; OSTEOMALACIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; REVIEW; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; BIOPSY; BONE; CHRONIC DISEASE;

BIOPSY; BONE AND BONES; BONE DENSITY; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; OSTEOPOROSIS;

EID: 70349576228     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0025-1     Document Type: Review

References (42)

1. S.E. Gabriel A.N. Tosteson C.L. Leibson, et al. 2002 Direct medical costs attributable to osteoporotic fractures Osteoporos Int 13 323 330 12035765 10.1007/s001980200033 1:STN:280:DC%2BD383psFGnsw%3D%3D (Pubitemid 34506742)
2. S. Moe T. Drüeke J. Cunningham, et al. 2006 Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 69 1945 1953 16641930 10.1038/sj.ki.5000414 1:STN:280:DC%2BD283ptl2nug%3D%3D (Pubitemid 43924257)
3. C.O. Stehman-Breen D.J. Sherrard A.M. Alem, et al. 2000 Risk factors for hip fractures among patients with end-stage renal disease Kidney Int 58 2200 2205 11044242 10.1111/j.1523-1755.2000.00394.x 1:STN:280: DC%2BD3M%2FivFSqsQ%3D%3D
4. M. Coco H. Rush 2000 Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone Am J Kidney Dis 36 1115 1121 11096034 10.1053/ajkd.2000.19812 1:STN:280:DC%2BD3M%2FnslWrtA%3D%3D
5. K. Atsumi K. Kushida K. Yamazaki, et al. 1999 Risk factors for vertebral fractures in renal osteodystrophy Am J Kidney Dis 33 287 293 10023640 10.1016/S0272-6386(99)70302-1 1:STN:280:DyaK1M7ks1antw%3D%3D
6. S.A. Jamal J.A. Hayden J. Beyene 2007 Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis Am J Kidney Dis 49 674 681 17472850 10.1053/j.ajkd.2007.02.264 (Pubitemid 46654494)
7. L.D. Quarles 2003 FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization Am J Physiol Endocrinol Metab 285 E1 E9 12791601 1:CAS:528:DC%2BD3sXls1Wntbg%3D
8. E. Ritz M.L. Gross 2005 Hyperphosphatemia in renal failure Blood Purif 23 6 9 15627730 10.1159/000082004 (Pubitemid 40082237)
9. F.R. Santos R.M. Moysés F.L. Montenegro, et al. 2003 IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy Kidney Int 63 899 907 12631070 10.1046/j.1523-1755.2003.00835. x (Pubitemid 36315567)
10. M. Kanatani T. Sugimoto J. Kano, et al. 2003 Effect of high phosphate concentration on osteoclast differentiation as well as bone resorbing activity J Cell Physiol 196 180 189 12767054 10.1002/jcp.10270 1:CAS:528: DC%2BD3sXksFeht7c%3D (Pubitemid 36676456)
11. T. Larsson R. Marsell E. Schipani, et al. 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis Endocrinology 145 3087 3094 14988389 10.1210/en.2003-1768 1:CAS:528:DC%2BD2cXltFyksrw%3D (Pubitemid 38829975)
12. D.K. Panda D. Miao I. Bolivar, et al. 2004 Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis J Biol Chem 279 16754 16766 14739296 10.1074/jbc.M310271200 1:CAS:528:DC%2BD2cXivF2qu7k%3D (Pubitemid 38509378)
13. A. Gal-Moscovici S. Sprague 2007 Bone health in chronic kidney disease-mineral bone density Adv Chronic Kidney Dis 14 27 36 17200041 10.1053/j.ackd.2006.10.010 (Pubitemid 46019904)
14. WHO Study Group: Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Geneva, Switzerland: World Health Organization; 1994.
15. B. Borah G.J. Gross T.E. Dufresne, et al. 2001 Three dimensional microimaging (MRmicroI and microCT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis Anat Rec 265 101 110 11323772 10.1002/ar.1060 1:STN:280:DC%2BD3M3ptlehuw%3D%3D (Pubitemid 32281262)
16. E. Seeman P.D. Delmas 2006 Bone quality-the material and structural basis of bone strength and fragility N Engl J Med 354 2250 2261 16723616 10.1056/NEJMra053077 1:CAS:528:DC%2BD28XkvVShsbw%3D
17. M.A. Fontaine A. Albert B. Dubois, et al. 2000 Fracture and bone mineral density in hemodialysis patients Clin Nephrol 54 218 226 11020020 1:STN:280:DC%2BD3cvmsVyntQ%3D%3D
18. P. Ureña O. Bernard-Poenaru A. Ostertag, et al. 2003 Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients Nephrol Dial Transplant 18 2325 2331 14551361 10.1093/ndt/gfg403 (Pubitemid 37345093)
19. A.L. Negri R. Barone M.A. Quiroga, et al. 2004 Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis Perit Dial Int 24 163 168 15119637
20. C. Díaz-Corte L.J. Fernández-Martín S. Barreto, et al. 2001 Effect of aluminum load on parathyroid hormone synthesis Nephrol Dial Transplant 16 742 745 11274267 10.1093/ndt/16.4.742
21. K.P. Nordal 1996 Calcium carbonate versus aluminum hydroxide as phosphate binder in hemodialysis patients. A randomized perspective study Kidney Int 49 926
22. S.M. Sprague 1988 Aluminum: its measurement and metabolism Sem Dialysis 1 103 111 10.1111/j.1525-139X.1988.tb00715.x
23. S.M. Sprague H. Abboud P. Qui, et al. 2009 Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial Clin J Am Soc Nephrol 4 178 185 19056618 10.2215/CJN.02830608 1:CAS:528: DC%2BD1MXitVWnurY%3D
24. M. Ketteler M. Rix S. Fan, et al. 2008 Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis Clin J Am Soc Nephrol 3 1125 1130 18450923 10.2215/CJN.05161107 1:CAS:528:DC%2BD1cXovFelu7Y%3D
25. P.C. D'Haese G.B. Spasovski A. Sikole, et al. 2003 A multicenter study on the effect of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients Kidney Int 85 S73 S78 10.1046/j.1523-1755.63. s85.18.x
26. E.A. González A. Sachdeva D.A. Oliver K.J. Martin 2004 Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study Am J Nephrol 24 503 510 15452403 10.1159/000081023 (Pubitemid 39656665)
27. A.L. Zisman M. Hristova L.T. Ho S.M. Sprague 2007 Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease Am J Nephrol 27 36 43 17215573 10.1159/000098561 1:CAS:528:DC%2BD2sXisFygsr8%3D (Pubitemid 46364539)
28. J. Coburn H.M. Maung L. Elangovan, et al. 2004 Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney diseases stages 3 and 4 Am J Kidney Dis 43 877 890 15112179 10.1053/j.ajkd.2004.01.012 1:CAS:528:DC%2BD2cXksVSksbk%3D (Pubitemid 38529626)
29. F. Takahashi J.L. Finch M. Denda, et al. 1997 A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content Am J Kidney Dis 30 105 112 9214408 10.1016/S0272-6386(97)90571-0 1:CAS:528:DyaK2sXkslakurw%3D
30. E. Slatopolsky J. Finch C. Ritter, et al. 1995 A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia Am J Kidney Dis 26 852 860 7485144 10.1016/0272-6386(95)90455-7 1:CAS:528:DyaK28XkslM%3D
31. S.M. Sprague F. Llach M. Amdahl, et al. 2003 Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism Kidney Int 63 1483 1490 12631365 10.1046/j.1523-1755.2003.00878.x 1:CAS:528:DC%2BD3sXjtVymur0%3D (Pubitemid 36350014)
32. D. Coyne M. Acharya P. Qui, et al. 2006 Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD Am J Kidney Dis 47 263 276 16431255 10.1053/j.ajkd.2005.10.007 1:CAS:528:DC%2BD28XhslWnt7o%3D (Pubitemid 43121329)
33. E. Slatopolsky M. Cozzolino Y. Lu, et al. 2003 Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia Kidney Int 63 2020 2027 12753289 10.1046/j.1523-1755.2003.00029.x 1:CAS:528:DC%2BD3sXkvVyiurg%3D (Pubitemid 36605813)
34. J. P. I. P. I. Jokihaara, et al. 2006 Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease J Bone Miner Res 21 745 751 16734389 10.1359/jbmr.060114 1:CAS:528:DC%2BD28Xlt1artb8%3D
35. P.D. Miller 2005 Treatment of osteoporosis in chronic kidney disease and end-stage renal disease Curr Osteoporos Rep 3 5 12 16036095 10.1007/s11914-005- 0021-y
36. Miller PD: Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In Osteoporosis, edn 3. Edited by Marcus R, Feldman D, Nelson DA, Rosen CJ. San Diego, CA: Elsevier Academic Press; 2007:1725-1736.
37. J.A. Eisman R. Civetelli S. Adami, et al. 2008 Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study J Rheumatol 35 488 497 18260172 1:CAS:528: DC%2BD1cXksFKjtrY%3D
38. D.M. Black P.D. Delmas R.R. Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D (Pubitemid 46698462)
39. E.M. Lewiecki P.D. Miller 2007 Renal safety of intravenous bisphosphonates in the treatment of osteoporosis Expert Opin Drug Saf 6 663 672 17967155 10.1517/14740338.6.6.663 1:CAS:528:DC%2BD2sXht1anu7%2FI (Pubitemid 351308278)
40. P.D. Miller E.N. Schwartz P. Chen, et al. 2007 Teriparatide in postmenopausal women with osteoporosis and impaired renal function Osteoporosis Int 18 59 68 10.1007/s00198-006-0189-8 1:CAS:528:DC%2BD28Xht1OhtrfP (Pubitemid 44885496)
41. P.D. Miller C. Roux S. Boonen, et al. 2005 Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials J Bone Miner Res 20 2105 2115 16294264 10.1359/JBMR.050817 1:CAS:528: DC%2BD2MXhtlWntrbN (Pubitemid 41698774)
42. S.A. Jamal D.C. Bauer K.E. Ensrud, et al. 2007 Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial J Bone Miner Res 22 503 508 17243862 10.1359/jbmr.070112 1:CAS:528:DC%2BD2sXpt1Grtr0%3D (Pubitemid 47457426)